HomeCompareCLSD vs PLD

CLSD vs PLD: Dividend Comparison 2026

CLSD yields 487.80% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLSD wins by $50747.39M in total portfolio value
10 years
CLSD
CLSD
● Live price
487.80%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50753.89M
Annual income
$36,168,404,531.85
Full CLSD calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — CLSD vs PLD

📍 CLSD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLSDPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLSD + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLSD pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLSD
Annual income on $10K today (after 15% tax)
$41,463.41/yr
After 10yr DRIP, annual income (after tax)
$30,743,143,852.07/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, CLSD beats the other by $30,738,675,881.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLSD + PLD for your $10,000?

CLSD: 50%PLD: 50%
100% PLD50/50100% CLSD
Portfolio after 10yr
$25380.20M
Annual income
$18,086,830,484.02/yr
Blended yield
71.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CLSD
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
Altman Z
-48.3
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLSD buys
0
PLD buys
0
No recent congressional trades found for CLSD or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLSDPLD
Forward yield487.80%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$50753.89M$6.50M
Annual income after 10y$36,168,404,531.85$5,256,436.18
Total dividends collected$49478.61M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: CLSD vs PLD ($10,000, DRIP)

YearCLSD PortfolioCLSD Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$59,480$48,780.49$11,255$555.24+$48.2KCLSD
2$334,811$271,167.03$13,062$1,018.59+$321.7KCLSD
3$1,784,770$1,426,522.08$15,903$1,926.67+$1.77MCLSD
4$9,016,553$7,106,848.63$20,839$3,823.32+$9.00MCLSD
5$43,202,271$33,554,559.81$30,464$8,166.08+$43.17MCLSD
6$196,483,123$150,256,693.49$52,054$19,457.30+$196.43MCLSD
7$848,895,486$638,658,543.63$109,886$54,188.93+$848.79MCLSD
8$3,487,095,949$2,578,777,778.75$304,030$186,451.18+$3486.79MCLSD
9$13,631,297,985$9,900,105,319.66$1,166,125$840,813.32+$13630.13MCLSD
10$50,753,893,375$36,168,404,531.85$6,504,190$5,256,436.18+$50747.39MCLSD

CLSD vs PLD: Complete Analysis 2026

CLSDStock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Full CLSD Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CLSD vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLSD vs SCHDCLSD vs JEPICLSD vs OCLSD vs KOCLSD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.